To the Editor:

Coronavirus disease 2019 (Covid-19), caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), is a disease with a clinical spectrum that ranges from asymptomatic to critical disease requiring Intensive Care Unit (ICU) admission, intubation, and prolonged mechanical ventilation due to a severe acute respiratory distress syndrome (ARDS) \[[@bb0005]\]. Despite the large and growing number of cases of Covid-19 disease around the world, there are few publications related to the performance of tracheostomies in Covid-19 patients who require prolonged mechanical ventilation. We describe our experience in 5 patients with laboratory-confirmed COVID-19 admitted in the ICU of Clinical Hospital of Santiago de Compostela who underwent elective bedside percutaneous dilational tracheostomies (PDT) during April 2020. This prospective case series was approved by the Research Ethics Committee of the Galicia, Spain, number 2020-188. Informed consent for the procedure was provided by all patients or a close relative of the patient. All patients were admitted with severe ARDS. Patient demographics, comorbidities, clinical ICU course and treatments are described in [Table 1](#t0005){ref-type="table"} . Tracheostomy was performed after a mean of 16 (13-27) days of invasive mechanical ventilation and the patients presented a PaO2/FiO2 ratio of 167 (92-206). PTD took place in ICU, in a closed room. Team that performed PTD consisted of 3 anesthesiologists and a circulation nurse. One anesthesiologist managed airway and bronchoscopy, and the other two performed the PTD. Each person wore standard personal protective equipment PPE (FFP3 mask, surgical cap, goggles, surgical gown, and double gloves). During procedure, all patients were deep sedated and paralyzed. During tracheal puncture mechanical ventilation was stopped and we used a Single-Step dilatation technique (Ciaglia Blue Rhino G2 Advanced Percutaneous Tracheostomy Kit (Cook Medical)) with the help of a bronchoscope to control the puncture site, the direction of guidewire, and the location of tracheostomy. PTD was performed at the bedside in all five patients without difficulty, and no complications were found. Neither the nurse nor the anesthetists who participated in the PTD developed symptoms or tested positive for Covid-19 fourteen days after procedure.Table 1Clinical Characteristics patients with severe ARDS by COVID-19 where tracheostomy was performed.Table 1Patient 1Patient 2Patient 3Patient 4Patient 5Characteristics Age, yr6870706368 Sex,FMMMM Weight, kg6592759097 Height, cm165165162176166 APACHE II score2117211620 PaO2/FiO2 in ICU admission (mmHg)18020692133173 PaO2 in ICU admission (mmHg)8012492106104 Chronic medical illness HypertensionNoYesYesNoYes DiabetesNoNoNoNoYes Chronic obstructive pulmonary diseaseYesNoNoNoNo Heart diseaseNoYesSiNoYes Laboratory parameters Leukocytes count per mL179808400480034507400 Lymphocytes count per mL2305101802801080 C-reactive protein, mg/L25155717 D-dimer, ng/mL487070719003571295 Lactate dehydrogenase, U/L989600248519913 Creatine kinase, ng/mL2911403311054 Serum Ferritin, μg/L53126506892898653 Interleukin-6, pg/mL15885181967077 Procalcitonin, ng/mL13,30,32640,460,22 Triglycerides, mg/dL127195118256117 Treatment HydroxychloroquineYesYesYesYesYes Lopinavir/ritonavirYesYesYesYesYes AzithromycinYesYesYesYesYes TocilizumabNoNoYesNoYes GlucocorticoidsYesYesYesYesYesClinical ICU course Duration since intubation to tracheostomy (days)1327171616 Length of ICU stay (days)3931384039[a](#tf0005){ref-type="table-fn"} Survival at 21 after PTDYesYesNoNoYes[^1]

PTD is a common, minimally invasive procedure to facilitate tracheostomy placement, and it represents an alternative to traditional open tracheostomy. We prefer to perform PTD because it is fast, safe, and with low complications. It is performed in our ICU at bedside, avoiding transport of Covid-19 patients to the operating room with repeated connection and disconnection of ventilatory circuits during transfer. Although open tracheostomies were favored over PTD during the SARS outbreak \[[@bb0010]\], techniques for PTD have advanced since then. We used a single stage "Rhino" dilator technique avoiding multiple entries. Procedure was performed under deep sedation and full neuromuscular blockade to prevent coughing, and we stopped mechanical ventilation just before performing the PTD, to minimize aerosol generation. Although the use of the bronchoscope could generate an increase in aerosols, we believe that it is worth using it due to the increased safety for the patient when performing the procedure. During the procedure we paid meticulous attention to the details of infection control, to minimize cross-contamination and our risk of contracting the illness \[[@bb0015],[@bb0020]\].

The optimal timing of tracheostomy in ventilated Covid-19 patients remains controversial. We perform our PTD 14 days after endotracheal intubation (IOT) as recommends the American of Otolaryngology-Head and Neck surgery \[[@bb0025]\].

In conclusion, there is no evidence whether PTD or surgical open tracheotomy is less aerosol generating. We considered that PTD may be a safe and effective technique for COVID-19 patients with ARDS. Future studies will determine the role of percutaneous tracheostomy in Covid-19 patients with difficult disconnection from mechanical ventilation.

Clinical trial number: Code No. 2020-188.
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